These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31698522)

  • 1. SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy.
    Kalra J; Mangali SB; Dasari D; Bhat A; Goyal S; Dhar I; Sriram D; Dhar A
    Fundam Clin Pharmacol; 2020 Apr; 34(2):173-188. PubMed ID: 31698522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
    Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
    J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
    Song P; Onishi A; Koepsell H; Vallon V
    Expert Opin Ther Targets; 2016 Sep; 20(9):1109-25. PubMed ID: 26998950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Na
    Koepsell H
    Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT inhibitors: a novel target for diabetes.
    Kanwal A; Banerjee SK
    Pharm Pat Anal; 2013 Jan; 2(1):77-91. PubMed ID: 24236972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myocardial glucotoxicity: Mechanisms and potential therapeutic targets.
    Battault S; Renguet E; Van Steenbergen A; Horman S; Beauloye C; Bertrand L
    Arch Cardiovasc Dis; 2020 Nov; 113(11):736-748. PubMed ID: 33189592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 8. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
    Scheen AJ; Paquot N
    Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors and the Treatment of Type 2 Diabetes.
    Kramer CK; Zinman B
    Annu Rev Med; 2019 Jan; 70():323-334. PubMed ID: 30256723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucose and blood pressure lowering effects of Pycnogenol® are inefficient to prevent prolongation of QT interval in experimental diabetic cardiomyopathy.
    Jankyova S; Kmecova J; Cernecka H; Mesarosova L; Musil P; Brnoliakova Z; Kyselovic J; Babal P; Klimas J
    Pathol Res Pract; 2012 Aug; 208(8):452-7. PubMed ID: 22749577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
    Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
    Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
    Danne T; Biester T; Kordonouri O
    Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.
    Abdul-Ghani MA; Norton L; Defronzo RA
    Endocr Rev; 2011 Aug; 32(4):515-31. PubMed ID: 21606218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT1 inhibition: Pros and cons.
    Tsimihodimos V; Filippas-Ntekouan S; Elisaf M
    Eur J Pharmacol; 2018 Nov; 838():153-156. PubMed ID: 30240793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of LX2761, a Sodium-Dependent Glucose Cotransporter 1 (SGLT1) Inhibitor Restricted to the Intestinal Lumen, for the Treatment of Diabetes.
    Goodwin NC; Ding ZM; Harrison BA; Strobel ED; Harris AL; Smith M; Thompson AY; Xiong W; Mseeh F; Bruce DJ; Diaz D; Gopinathan S; Li L; O'Neill E; Thiel M; Wilson AG; Carson KG; Powell DR; Rawlins DB
    J Med Chem; 2017 Jan; 60(2):710-721. PubMed ID: 28045524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental type II diabetes and related models of impaired glucose metabolism differentially regulate glucose transporters at the proximal tubule brush border membrane.
    Chichger H; Cleasby ME; Srai SK; Unwin RJ; Debnam ES; Marks J
    Exp Physiol; 2016 Jun; 101(6):731-42. PubMed ID: 27164183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
    Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
    Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
    Gallo LA; Wright EM; Vallon V
    Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?
    Rajasekeran H; Cherney DZ; Lovshin JA
    Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):358-367. PubMed ID: 28582367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure.
    Verbrugge FH
    Curr Heart Fail Rep; 2017 Aug; 14(4):275-283. PubMed ID: 28647919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.